Biodesix: Funding, Investors & Team (Sep 2026)
Biodesix is a company that utilizes data-driven diagnostic solutions to provide lung cancer testing and services to the biopharma industry. They offer physicians diagnostic tests for early disease detection, accurate diagnosis, monitoring, and guidance for better treatment options. Through their proprietary mass spectrometry-based platform, Biodesix develops and commercializes multivariate protein diagnostics, with VeriStrat being their first product using this technology. This test helps oncologists decide between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Results from Biodesix's CLIA-certified lab are reported in less than 72 hours. In addition to their own diagnostic development, the company collaborates with biotech and pharma companies to create companion diagnostics for improved therapeutic use.
Biodesix has raised $105M across 2 funding rounds on record, the most recent an undisclosed round of $55.0M announced in Apr 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Biodesix Company Profile and Key Stats
Latest funding round on record: Apr 2024.
Biodesix Funding Rounds
Biodesix raised $50.0M in a Post-IPO Equity announced in Mar 2022.
2.1 years later, an undisclosed round of $55.0M was announced in Apr 2024.
Biodesix Founders and Leadership Team
Contact details for the Biodesix team: 2 of 2 have an email address on file.
Start 14-day free trial →Biodesix Funding Compared to Other Biotechnology Startups
Biodesix's latest round of $55.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Biodesix in Biotechnology and Broomfield
Companies Similar to Biodesix
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Biodesix Funding FAQs
What does Biodesix do?
Biodesix is a company that utilizes data-driven diagnostic solutions to provide lung cancer testing and services to the biopharma industry. They offer physicians diagnostic tests for early disease detection, accurate diagnosis, monitoring, and guidance for better treatment options. Through their proprietary mass spectrometry-based platform, Biodesix develops and commercializes multivariate protein diagnostics, with VeriStrat being their first product using this technology. This test helps oncologists decide between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Results from Biodesix's CLIA-certified lab are reported in less than 72 hours. In addition to their own diagnostic development, the company collaborates with biotech and pharma companies to create companion diagnostics for improved therapeutic use.
How much funding has Biodesix raised?
Biodesix has raised $105M across 2 rounds on record. The most recent is an undisclosed round of $55.0M announced in Apr 2024.
When did Biodesix last raise funding?
Biodesix's most recent funding round on record is an undisclosed round of $55.0M, announced in Apr 2024.
Who founded Biodesix?
FundedIQ lists Heinrich Roder (Founder) at Biodesix.
Who is the CEO of Biodesix?
Scott Hutton is listed as CEO at Biodesix.
Where is Biodesix headquartered?
Biodesix is based in Broomfield, Colorado, United States.
How many employees does Biodesix have?
Biodesix is in the 101-250 employee band.
How does Biodesix's funding compare to other Biotechnology startups?
Biodesix's latest round of $55.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Biodesix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Biodesix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.